A Look at Three-Year Data for Pegcetacoplan

Ashkan Abbey, MD

Show Description +

Ashkan Abbey, MD, reviews the efficacy and safety of pegcetacoplan (Syfovre, Apellis) over 36 months, and touches on 12-month results of the GALE open-label extension study.

Posted: 5/17/2024

Keywords:

retina-meeting-recap

•

Pegcetacoplan

•

syfovre

•

Apellis

•

Apellis

•

Clinical Trials

•

Geographic Atrophy (GA)

Up Next

Name: A Look at Three-Year Data for Pegcetacoplan
Uploaded: 2024-05-17T15:17:23+00:00
Description: Ashkan Abbey, MD, reviews the efficacy and safety of pegcetacoplan (Syfovre, Apellis) over 36 months, and touches on 12-month results of the GALE open-label extension study.

The Latest Data on Photobiomodulation

Todd Schneiderman, MD

A Subretinal Implant for GA: Improving Vision

Mahi Muqit, MD

Optogenetics for RP: 12-Month Data

Allen Ho, MD

New Data on Oral DR Therapy

Daniel Su, MD

Outcomes with 8 mg Aflibercept: Does Prior DME Treatment Matter?

Nitish Mehta, MD

Imaging AMD: Microperimetry and OCT

Giulia Corradetti, MD

SriniVas R. Sadda, MD, Steps in as ARVO President

Vas Sadda, MD

Gene Therapy for Wet AMD: Pharmacodynamic Changes

Ramanath Bhandari, MD

Faricimab in the Real World: 2 Years of Data

Aamir Aziz, MD

Addressing the AMD Epidemic

Emily Chew, MD

Managing Concurrent Wet AMD and GA

Ted Leng, MD

Back to All Videos

A Look at Three-Year Data for Pegcetacoplan

Ashkan Abbey, MD

Ashkan Abbey, MD, reviews the efficacy and safety of pegcetacoplan (Syfovre, Apellis) over 36 months, and touches on 12-month results of the GALE open-label extension study.

Posted: 5/17/2024

Keywords:

retina-meeting-recap

•

Pegcetacoplan

•

syfovre

•

Apellis

•

Apellis

•

Clinical Trials

•

Geographic Atrophy (GA)

Please log in to leave a comment.

Meeting Coverage:

Association for Research in Vision & Ophthalmology

A Look at Three-Year Data for Pegcetacoplan

Up Next

A Look at Three-Year Data for Pegcetacoplan

More From ARVO: 2024 Coverage